Subsequently, the DESTINY-Breast03 trial compared T-DXd to T-DM1 as second-line treatments for advanced HER2+ breast cancer following treatment with first-line trastuzumab, pertuzumab and taxane chemotherapy (62% of participants were previously treated with pertuzumab) [15]. The gene discussed is ERBB2; the disease is breast carcinoma.